Higher Pentraxin-3 Levels are Associated With Inflammation in Familial Mediterranean Fever by Bulut, M. et al.
Higher Pentraxin-3 Levels are Associated With Inflammation
in Familial Mediterranean Fever
Mesudiye Bulut,1 Mevlut Ceri,2∗ Selman Unverdi,3 Mustafa Altay,4 Mehmet Senes,5
Zafer Aydın Ecemis,6 and Murat Duranay3
1Department of Nephrology, Numune Education and Research Hospital, Ankara, Turkey
2Department of Nephrology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
3Department of Nephrology, Ankara Education and Research Hospital, Ankara, Turkey
4Department of Endocrinology, Kecioren Education and Research Hospital, Ankara, Turkey
5Department of Biochemistry, Ankara Education and Research Hospital, Ankara, Turkey
6Department of Internal Medicine, Ankara Education and Research Hospital, Ankara, Turkey
Background: Circulating levels of Pentraxin-
3 (PTX3) have been shown to increase in
several inflammatory conditions. However,
there is no information about the levels of
PTX3 in patients with familial Mediterranean
fever (FMF). This study was designed to
evaluate the serum PTX3 levels in patients
with FMF during attack and free-attack pe-
riods. Methods: Twenty FMF patients in at-
tack and free-attack period, and 20 age-,
sex-, and body mass index-matched healthy
controls were included in the study. Blood
samples were obtained within the first 24 h
of the attack period and between attacks,
and levels of white blood cell, erythrocyte
sedimentation rate, Fibrinogen, high sen-
sitive CRP, and PTX3 were determined.
Results: PTX3 levels during the attack pe-
riod were not significantly different from
those in free-attack patients (4.9 ± 4.6 ng/ml
vs. 2.8 ± 1.4 ng/ml, P > 0.05). However,
both attack and free-attack patients had sig-
nificantly higher PTX3 levels than healthy
controls (4.9 ± 4.6 ng/ml vs. 1.8 ± 0.8
ng/ml, P < 0.001; 2.8 ± 1.4 ng/ml vs. 1.8
± 0.8 ng/ml, P < 0.025, respectively). Con-
clusions: PTX3 levels were not markedly
affected from FMF attacks, but high level
of PTX3 in free-attack period of FMF pa-
tients shows ongoing subclinical inflamma-
tion. However, further studies are needed
to determine its usefulness as a marker in
clinical practice. J. Clin. Lab. Anal.
2016. C© 2016 Wiley Periodicals, Inc.
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INTRODUCTION
Familial Mediterranean fever (FMF), an autosomal
recessive disease, is characterized by recurrent aseptic in-
flammation of serosal membranes. Although the Mediter-
ranean fever (MEFV) gene has been identified, the diag-
nosis of this disease is predominantly based on clinical
parameters (1, 2). Moreover, clinical attacks are accom-
panied by mild leukocytosis and increased acute-phase
reactants such as erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), fibrinogen, serum amyloid A,
interleukin (IL)-6, and tumor necrosis factor (TNF) (1–3).
Pentraxin-3 (PTX3) is a multimeric inflammatory me-
diator secreted by especially leukocytes and endothelial
cells. This protein is stored in neutrophils and increased
rapidly in response to proinflammatory signals. PTX3
activates the classical pathway of the complement ac-
tivation, modulates the phagocytic uptake of apoptotic
cells by macrophages and dendritic cells, and also inhibits
leukocyte recruitment by interacting with P-selectin (4–6).
High PTX3 levels have been shown to be associated with
inflammatory conditions and autoimmune disorders in
recently published studies (5), however role of PTX3 in the
inflammatory response in FMF has not been investigated.
This study was designed to evaluate the serum PTX3 levels
∗Correspondence to: Mevlut Ceri, Nefroloji Klinigi, Pamukkale
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in FMF disease during attack and attack-free periods, and
to determine whether PTX3 could contribute to diagnosis
of attack in FMF.
MATERIALS AND METHODS
This study was conducted in our outpatient nephrology
unit. Forty patients previously diagnosed with FMF, who
met the diagnostic criteria suggested by Livneh et al. (7),
and 20 healthy volunteers of similar age and gender as the
control group were included in the study. All participants
were further evaluated in three groups—Group I: attack
group (n = 20), Group II: attack-free group (n = 20),
Group III: control (n = 20). The study was reviewed and
approved by the ethics committee of our hospital, and an
inform consent was obtained by all participants. Detailed
medical history and physical examination of the partici-
pants were recorded. Patients with abnormal hepatic and
renal functions, malignancy, rheumatologic disease, acute
infection, chronic inflammation, and pregnant or breast-
feeding patients were excluded. No drug was used other
than colchicine (1–2 mg/day). All patients were investi-
gated in terms of FMF gene mutation.
Blood samples were collected from the attack-free
and control groups after 12 h of fasting. On follow-up,
blood samples were taken from patients suffering from
attack within 24 h after the attack started. All sam-
ples were stored at −80°C until assayed. High sensitive
CRP (hsCRP) was measured by the immunonephelomet-
ric method, and in addition white blood cell (WBC) count,
ESR, fibrinogen levels were determined by routine labora-
tory methods. Serum PTX-3 levels were measured by us-
ing a commercially available enzyme-linked immunosor-
bent assay kit (Human Pentraxin-3/TSG-14 Quantikine,
R&D Systems).
All statistical analyses were performed by using the
SPSS for Windows, version 15.0 (Chicago, IL). The data
were presented as mean ± SD. The frequencies were
calculated for each group, and comparisons were made
for categorical variables using Chi-square test. Numeri-
cal data were compared by using Mann–Whitney U test.
Pearson’s correlation test was used to evaluate possible
correlations between quantitative variables. P value of
<0.05 was considered statistically significant.
RESULTS
The demographic and laboratory characteristics of the
FMF and control groups are presented in Table 1. Fever
(90%) and abdominal pain (80%) were the most common
symptoms, followed by arthritis (65%) and chest pain
(10%) in FMF attacks. Interestingly, skin lesions were
observed in two patients (10%). Among the 40 patients
with FMF, MEFV mutations were identified in 35 cases
(87.5%) and the most common mutation was M694V
(47.5%).
All acute-phase reactants and PTX3 levels were found
increased significantly during the FMF attacks compared
to the control group (PTX3; 4.9 ± 4.6 vs. 1.8 ± 0.8, P =
0.001, Fig. 1). In attack-free period, we found hsCRP,
fibrinogen, and PTX3 levels higher than the control group
(8.6 ± 10.2 vs. 2.9 ± 3.0, P = 0.04; 392.1 ± 78.9 vs.
329.1 ± 72.8, P = 0.02; 2.8 ± 1.4 vs.1.8 ± 0.8, P = 0.025,
respectively, Fig. 1). However, ESR and WBC levels were
similar between the attack-free patients and the healthy
subjects (P > 0.05). The values of hsCRP, fibrinogen,
and WBC were significantly higher in the attack group
compared to the attack-free group (79.8 ± 54.8 vs. 8.6
± 10.2, P = 0.001; 475.8 ± 118.1 vs. 392.1 ± 78.9, P =
0.01; 11.9 × 103 ± 6.1 × 103 vs. 7.8 × 103 ± 2.5 × 103,
P = 0.007, respectively). Although serum PTX3 levels
were increased to some extent during the attacks, this was
not significant statistically (4.9 ± 4.6 vs. 2.8 ± 1.4, P >
0.05, Fig. 1). Additionally, there was positive correlation
between the serum PTX3 levels and WBC, fibrinogen,
hsCRP levels in attack period (r = 0.628, r = 0.515, r =
0.504, respectively, P < 0.05). There was no correlation
between these parameters in the attack-free and control
TABLE 1. Characteristics of the Study Groups
Attack group (n = 20) Attack-free group (n = 20) Control group (n = 20)
Sex, male/female 8/12 9/11 5/15
Age 29.55 ± 9.0 32.75 ± 10.12 32.85 ± 13.83
BMI (kg/m2) 23.60 ± 3.53 23.75 ± 3.83 21.83 ± 1.07
WBC (mm3) 11.9 × 103 ± 6.1 × 103a,b 7.8 × 103 ± 2.5 × 103 7.2 × 103 ± 1.2 × 103
ESR (mm/h) 30.8 ± 22.1a 18.7 ± 13.7 11.9 ± 10.9
Fibrinojen (mg/dL) 475.8 ± 118.1a,b 392.1 ± 78.9a 329.1 ± 72.8
hsCRP (mg/dL) 79.8 ± 54.8a,b 8.6 ± 10.2a 2.9 ± 3.0
PTX3 (ng/ml) 4.9 ± 4.6a 2.8 ± 1.4a 1.8 ± 0.8
aP < 0.05 as compared with control.
bP < 0.05 as compared with FMF attack-free.
BMI, body mass index.
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Fig. 1. Levels of PTX3 in patients with FMF and healthy controls.
groups. WBC, hsCRP, fibrinogen, ESR, and PTX3 levels
did not show significant differences between the M694V
and other mutations in FMF study groups.
DISCUSSION
In the present study, we aimed to evaluate the serum
PTX3 levels in FMF disease during the attack and attack-
free periods. We found that PTX3 level was significantly
higher in both attack and attack-free patients than that of
controls; however the increased PTX3 in the attack period
was not statistically significant as compared to attack-free
periods.
FMF is characterized by periodic febrile episodes and
the attack limits itself rapidly. Although the genetic de-
fect is known, the mechanisms of this defect caused by
inflammatory attacks are largely unclear. Probably, mu-
tated pyrin leads to uncontrolled inflammation by the
production of IL-1 and to the inhibition of apoptosis of
leukocytes (2). PTX3 production is induced by IL-1 and
TNF-α, and it inhibits the clearance of late apoptotic neu-
trophils by macrophages. Therefore, it may be a candidate
factor for the development of attacks and inhibition of
apoptosis (5). However, our study could not indicate sta-
tistically significant increase in serum PTX3 levels during
attack periods.
Serum PTX3 level increases rapidly in inflammatory
conditions such as sepsis, myocardial infarction, and
surgery. PTX3 reaches peak values after 6–8 h of any
inflammatory condition, and the early phase of its eleva-
tion is due to rapid release of stored PTX3 by activated
neutrophils (4, 5, 8). In our study, we were able to de-
tect significant increase of serum PTX3 levels in the at-
tack group as compared to the control. Based on these
findings, it may be speculated that PTX3 can be consid-
ered as an early supporting marker for diagnosis in the
inflammatory diseases such as FMF.
Colchicine is used to prevent recurrent attacks of FMF
characterized by neutrophil infiltration. In addition, both
regression of inflammation and improvement in daily
activities are documented after colchicine usage dur-
ing attack-free period (3, 9). This is probably due to
suppressing effect of colchicine on leukocyte degranu-
lation/chemotaxis and production of the inflammatory
mediators such as CRP and IL-1, or on activity of the
complement cascade (3,10). In our study, we were unable
to identify a significant increase in PTX3 levels during at-
tacks. Therefore, we believe that this might be due to reg-
ular use of colchicine in the patients. Prospective studies
comparing groups with and without colchicine treatment
are necessary in order to determine the role of colchicine,
but it is unethical to cease colchicine in these patients.
FMF is characterized by attacks of painful inflamma-
tion, but this presentation represents only the tip of the
iceberg. In many patients with FMF, inflammation can
persist in attack-free periods as shown by high levels
of acute-phase proteins and cytokines (3). In our study,
PTX3 level was found to be significantly higher in attack-
free patients than that of controls. This result suggests
that PTX3 may be an indicator of chronic inflammation
in FMF patients or its high levels might contribute to sub-
clinical inflammation in these patients.
Recently, various studies have reported the association
between cardiovascular events and inflammation. CRP,
a prototypic pentraxin, is an independent risk factor for
cardiovascular events and atherosclerosis in healthy and
high-risk subjects. Moreover, some studies suggest that
strong PTX3 expression was found in macrophages
and endothelial cells in advanced atherosclerotic lesions
(5, 11). In few recent studies, it has been shown that
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endothelial dysfunction, increased atherosclerosis, and
activation of platelets accompany attack-free periods
of FMF, and these conditions are usually characterized
by subclinical inflammation with production of excessive
acute-phase reactants (11, 12). Both PTX3 and hsCRP
levels were elevated in attack-free periods in the present
study, therefore higher PTX3 might be a marker for car-
diovascular events and increased atherosclerosis in FMF
disease. However, further studies are needed to define its
role in atherosclerosis.
There are some limitations in our study. First, we had
limited number in each group, which limits the power to
detect changes in a marker as variable as PTX3. Second,
inflammatory markers such as serum amyloid A, IL-1, IL-
6, and TNF-α could be added to traditional acute-phase
reactants, but they are not available in every laboratory.
In conclusion, PTX3 levels were not obviously affected
from acute attacks and could not be used as a support-
ive marker to differentiate attacks from attack-free peri-
ods. However, high level of PTX3 in FMF disease shows
ongoing subclinical inflammation. Further studies are
needed to determine its usefulness as a marker in clinical
practice.
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